CR20220014A - Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos - Google Patents

Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos

Info

Publication number
CR20220014A
CR20220014A CR20220014A CR20220014A CR20220014A CR 20220014 A CR20220014 A CR 20220014A CR 20220014 A CR20220014 A CR 20220014A CR 20220014 A CR20220014 A CR 20220014A CR 20220014 A CR20220014 A CR 20220014A
Authority
CR
Costa Rica
Prior art keywords
pyridazin
diamino
pro
derivatives
pharmaceutical compositions
Prior art date
Application number
CR20220014A
Other languages
English (en)
Inventor
Simon Bedford
Miklós Nyerges
András Kotschy
Jérôme-Benoît Starck
András Herner
Monika Rudasová
Marianna Szigeti
Paul Webb
Márk Molnár
Mátyás Pál Timári
Tibor Novák
Petra Dunkel
Ágnes Strofek
James Edward Paul Davidson
James Brooke Murray
Maïa Chanrion
Patrice Desos
Attila Paczal
Frédéric Colland
Mark Philip Dodsworth
Ana Leticia Maragno
Zoltán Madarász
Rachel Jane Parsons
Original Assignee
Vernalis R&D Ltd
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd, Servier Lab filed Critical Vernalis R&D Ltd
Publication of CR20220014A publication Critical patent/CR20220014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos de fórmula (I) en donde Het1, Het2, R1, R2 y R3 son como se definen en la descripción. Medicamentos.
CR20220014A 2019-07-29 2020-07-28 Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos CR20220014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19188747 2019-07-29
PCT/EP2020/071179 WO2021018857A1 (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Publications (1)

Publication Number Publication Date
CR20220014A true CR20220014A (es) 2022-03-02

Family

ID=67514281

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220014A CR20220014A (es) 2019-07-29 2020-07-28 Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos

Country Status (19)

Country Link
US (1) US20220289734A1 (es)
EP (1) EP4003988A1 (es)
JP (1) JP2022542937A (es)
KR (1) KR20220042182A (es)
CN (1) CN114450283B (es)
AR (1) AR119493A1 (es)
AU (1) AU2020322072A1 (es)
BR (1) BR112022001330A2 (es)
CA (1) CA3148502A1 (es)
CL (1) CL2021003594A1 (es)
CO (1) CO2022000700A2 (es)
CR (1) CR20220014A (es)
IL (1) IL289932A (es)
JO (1) JOP20220006A1 (es)
MX (1) MX2022001161A (es)
PE (1) PE20220704A1 (es)
TW (1) TW202118761A (es)
UY (1) UY38809A (es)
WO (1) WO2021018857A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553811A (ja) * 2020-11-24 2023-12-26 ノバルティス アーゲー Ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用方法
KR20230170644A (ko) * 2021-02-02 2023-12-19 르 라보레또레 쎄르비에르 선택적 bcl-xl protac 화합물 및 사용 방법
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503796A (ja) * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
EP2231656A1 (en) * 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SI3305785T1 (sl) * 2015-05-29 2021-11-30 Teijin Pharma Limited Derivat pirido(3,4-D)pirimidina in njegova farmacevtsko sprejemljiva sol

Also Published As

Publication number Publication date
WO2021018857A1 (en) 2021-02-04
BR112022001330A2 (pt) 2022-05-17
US20220289734A1 (en) 2022-09-15
JP2022542937A (ja) 2022-10-07
CA3148502A1 (en) 2021-02-04
CL2021003594A1 (es) 2022-11-18
TW202118761A (zh) 2021-05-16
PE20220704A1 (es) 2022-05-04
IL289932A (en) 2022-03-01
CN114450283A (zh) 2022-05-06
KR20220042182A (ko) 2022-04-04
CO2022000700A2 (es) 2022-02-07
AR119493A1 (es) 2021-12-22
MX2022001161A (es) 2022-02-22
JOP20220006A1 (ar) 2023-01-30
AU2020322072A1 (en) 2022-02-10
UY38809A (es) 2021-02-26
EP4003988A1 (en) 2022-06-01
CN114450283B (zh) 2024-05-07

Similar Documents

Publication Publication Date Title
CR20220014A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
TW200801003A (en) Novel compounds
ATE433447T1 (de) Pyrimiidinverbindungen
TW200610527A (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
SE0301700D0 (sv) Novel compounds
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TW200800931A (en) Novel piperazines as antimalarial agents
TW200738659A (en) Novel compounds
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
SE0302192D0 (sv) Novel compounds
TW200833670A (en) Novel compounds 569
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2009012117A (es) Composiciones y derivados heterociclicos sustituidos y su uso farmaceutico como antibacterianos.
GB0415365D0 (en) Pyrimidine derivatives
MX2021004000A (es) Derivados de piperidina.
TW200639156A (en) New compounds
CR20210216A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
TW200604197A (en) New compounds
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
MX2021014680A (es) Derivado de benzotriazol.
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.